Verwaest C, Verhaegen J, Ferdinande P, Schetz M, Van den Berghe G, Verbist L, Lauwers P
Department of Intensive Care Medicine, University Hospital Gasthuisberg, Leuven, Belgium.
Crit Care Med. 1997 Jan;25(1):63-71. doi: 10.1097/00003246-199701000-00014.
To evaluate the efficacy of two regimens of selective decontamination of the digestive tract in mechanically ventilated patients.
Prospective, randomized, concurrent trial.
Multidisciplinary intensive care unit (ICU) in a 1,800-bed university hospital.
Consecutive patients (n = 660) who were likely to require mechanical ventilation for at least 48 hrs were randomized to one of three groups: conventional antibiotic regimen (control group A); oral and enteral ofloxacin-amphotericin B (group B); and oral and enteral polymyxin E-tobramycin-amphotericin B (group C). Both treatment groups received systemic antibiotics for 4 days (ofloxacin in group B and cefotaxime in group C).
Patients were randomized to receive standard treatment (control group A, n = 220), selective decontamination regimen B (group B, n = 220), and selective decontamination regimen C (group C, n = 220). After early deaths and exclusions from the study, 185 controls (group A) and 193 (group B)/200 (group C) selective decontamination regimen patients were available for analysis.
Measurements included colonization and primary/secondary infection rate, ICU mortality rate, emergence of antibiotic resistance, length of ICU stay, and antimicrobial agent costs. The study duration was 19 months. The patient groups were fully comparable for age, diagnostic category, and severity of illness. One third of patients in each group suffered a nosocomial infection at the time of admission. There was a significant difference between treatment group B and control group A in the number of infected patients (odds ratio of 0.42, 95% confidence interval of 0.27 to 0.64), secondary lower respiratory tract infection (odds ratio of 0.47, 95% confidence interval of 0.26 to 0.82), and urinary tract infection (odds ratio of 0.47, 95% confidence interval of 0.27 to 0.81). Significantly more Gram-positive bacteremias occurred in treatment group C vs. group A (odds ratio of 1.22, 95% confidence interval 0.72 to 2.08). Infection at the time of admission proved to be the most significant risk factor for subsequent infection in control and both treatment groups. ICU mortality rate was almost identical (group A 16.8%, group B 17.6%, and group C 15.5%) and was not significantly related to primary or secondary infection. Increased antimicrobial resistance was recorded in both treatment groups: tobramycin-resistant enterobacteriaceae (group C 48% vs. group A 14%, p < .01), ofloxacin-resistant enterobacteriaceae (group B 50% vs. group A 11%, p < .02), ofloxacin-resistant nonfermenters (group B 81% vs. group A 52%, p < .02), and methicillin-resistant Staphylococcus aureus (group C 83% vs. group A 55%, p < .05). Antimicrobial agent costs were comparable in control and group C patients; one third less was spent for group B patients.
In cases of high colonization and infection rates at the time of ICU admission, the preventive benefit of selective decontamination is highly debatable. Emergence of multiple antibiotic-resistant microorganisms creates a clinical problem and a definite change in the ecology of environmental, colonizing, and infecting bacteria. The selection of multiple antibiotic-resistant Gram-positive cocci is particularly hazardous. No beneficial effect on survival is observed. Moreover, selective decontamination adds substantially to the cost of ICU care.
评估两种消化道选择性去污方案对机械通气患者的疗效。
前瞻性、随机、同期试验。
一所拥有1800张床位的大学医院的多学科重症监护病房(ICU)。
连续入选的可能需要机械通气至少48小时的患者(n = 660)被随机分为三组之一:传统抗生素方案(A对照组);口服及肠内给予氧氟沙星-两性霉素B(B组);口服及肠内给予多粘菌素E-妥布霉素-两性霉素B(C组)。两个治疗组均接受全身性抗生素治疗4天(B组用氧氟沙星,C组用头孢噻肟)。
患者被随机分配接受标准治疗(A对照组,n = 220)、选择性去污方案B(B组,n = 220)和选择性去污方案C(C组,n = 220)。在早期死亡和排除出研究后,185例对照组(A组)患者以及193例(B组)/200例(C组)接受选择性去污方案的患者可供分析。
测量指标包括定植及原发性/继发性感染率、ICU死亡率、抗生素耐药性的出现、ICU住院时间以及抗菌药物费用。研究持续时间为19个月。各患者组在年龄、诊断类别及疾病严重程度方面具有完全可比性。每组中有三分之一的患者在入院时发生医院感染。治疗组B与对照组A在感染患者数量(比值比为0.42,95%置信区间为0.27至0.64)、继发性下呼吸道感染(比值比为0.47,95%置信区间为0.26至0.82)及尿路感染(比值比为0.47,95%置信区间为0.27至0.81)方面存在显著差异。治疗组C与A组相比,革兰阳性菌血症的发生率显著更高(比值比为1.22,95%置信区间为0.72至2.08)。入院时的感染被证明是对照组和两个治疗组后续感染的最显著危险因素。ICU死亡率几乎相同(A组16.8%,B组17.6%,C组15.5%),且与原发性或继发性感染无显著相关性。两个治疗组均出现抗菌药物耐药性增加:对妥布霉素耐药的肠杆菌科细菌(C组48% vs A组14%,p <.01)、对氧氟沙星耐药的肠杆菌科细菌(B组50% vs A组11%,p <.02)、对氧氟沙星耐药的非发酵菌(B组81% vs A组52%,p <.02)以及耐甲氧西林金黄色葡萄球菌(C组83% vs A组55%,p <.05)。对照组和C组患者的抗菌药物费用相当;B组患者的花费减少了三分之一。
在ICU入院时定植和感染率较高的情况下,选择性去污的预防益处极具争议。多种抗生素耐药微生物的出现造成了临床问题,并且环境、定植及感染细菌的生态发生了明确变化。多重耐药革兰阳性球菌的选择尤其危险。未观察到对生存的有益影响。此外,选择性去污大幅增加了ICU护理的费用。